Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 4/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778410 | 0.88 | MRGPRX1 (0.41) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778833 | 0.88 | PTGS1 (0.40) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778567 | 0.87 | PTGS1 (0.44) | PTGS1PTGS2CA2MRGPRX1CCR9 | |
| SCHEMBL12778623 | 0.87 | PTGS1 (0.39) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL2081633 | 0.86 | MRGPRX1 (0.39) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL2081631 | 0.86 | MRGPRX1 (0.39) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778748 | 0.86 | MRGPRX1 (0.45) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778566 | 0.86 | KMT2A (0.45) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778407 | 0.85 | MRGPRX1 (0.41) | PTGS1PTGS2CA2MRGPRX1ACLY | |
| SCHEMBL12778439 | 0.85 | SLC22A12 (0.43) | PTGS1PTGS2CA2ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906538-B2 | Parasiticides; nematocides; crop protection | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2008-10-23 | — | — | US | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312248-B2 | Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262048-A1 | CONTROL OF PARASITES IN ANIMALS BY THE USE OF NOVEL TRIFLUOROMETHANESULFONANILIDE OXIME ETHER DERIVATIVES | TRHDE, EPX, EPHX1 | PTGS1 1610/4885PTGS2 1554/4885CA2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.